Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

The U.S. health officials have recommended a pause in the use of French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) ...

The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...

Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what ...

The decision was taken following a plenary meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) on May 5, 2025 and is based on reports of 17 SAEs worldwide (including two deaths) in ...

Valneva (VALN) stock slips as the EU drug regulator suspends chikungunya vaccine for adults 65+ over safety concerns. Read ...

Columbia University and NewYork-Presbyterian Hospital agreed to pay $750 million to settle hundreds of sexual abuse claims ...

As a temporary measure, while this review is ongoing, EMA has suspended the use of the vaccine for individuals over 65 years old. EMA has maintained current recommendations for IXCHIQ ® for ...